High-Cost CAR-T Cancer Therapy Set for Breakthrough in 2025 Commercial Insurance Price Negotiations

At around 15:00 on November 2, at the site of the 2025 National Medical Insurance Catalogue live negotiations and commercial insurance innovative drug price consultations, Juventas' negotiation representative could not hide their joy after concluding price consultations, directly stating, "We succeeded in our negotiations." However, the final outcome will be subject to the official announcement by the National Healthcare Security Administration. This indicates that CAR-T drugs, including Juventas’ Naciorcels Injection, are expected to achieve a breakthrough in this year's commercial insurance innovative drug price consultations. Note: Juventas' Naciorcels Injection was approved for marketing in 2023, and it represents one of five CAR-T drugs that passed the form review for inclusion in the commercial insurance innovative drug catalogue this year. Due to their high cost, over the past four years, CAR-T therapies have consistently failed to meet the "threshold" for national medical insurance negotiations. (Reporters Chao Wu and Fan He, Cailian Press)